Rapid ART: An Essential Strategy to End the HIV Epidemic
Resource updated 03/15/2023
Resource updated 03/15/2023
Sample agreement submitted via the CAREWare listserv.
Resource updated 09/19/2023
Resource updated 09/19/2023
Sample user agreement submitted via the CAREWare listserv.
Resource updated 09/19/2023
Resource updated 09/19/2023
Resource updated 09/19/2023
Staff will present a population-based, data-driven approach to the Minority AIDS Initiative (MAI) funding designed to improve program engagement and retention to reduce health disparities and maximize health outcomes. Presenters will review methods to facilitate replication of the model in other Ryan White programs.
Resource (Conference Presentation) updated 09/14/2023
This discussion will give an overview of the methods and techniques used to handle a workforce that was comfortable with the status quo after 20 years of using CAREWare versions 1 through 5 and not ready to give in to change very quickly.
Resource (Conference Presentation) updated 09/14/2023
Resource (Conference Presentation) updated 09/14/2023
Resource (Conference Presentation) updated 09/14/2023
Resource (Conference Presentation) updated 09/14/2023
Resource (Conference Presentation) updated 09/14/2023
As HIV elimination activities increase, jurisdictions can address HIV/Hepatitis C (HCV) co-infection by enhancing HCV screening and treatment data collection. This session will discuss NASTAD's work with North Carolina to incorporate HCV data in CAREWare and electronic health records (EHRs), as well as recommendations for integrating HCV services into the HIV care infrastructure.
Resource (Conference Presentation) updated 09/14/2023
Rapid has developed into a core feature of the Dorothy Mann Center HIV care continuum, assuring immediate linkage to expert HIV services, immediate initiation of therapy, and rapid viral suppression. Benefits are present for youth prevention services. Rapid access models are feasible and beneficial for youth HIV care and prevention.
Resource (Conference Presentation) updated 09/14/2023
A clinic-based substance abuse screening and treatment program is described. Using the Screening, Brief Intervention, and Referral to Treatment model, this provides annual proactive screening of alcohol/drug use, with a brief provider response and a follow-up motivational interviewing brief intervention, with treatment provided by an embedded provider.
Resource (Conference Presentation) updated 09/14/2023
Oklahoma has been classified by the Department of Health and Human Services as one of the seven states with a high rural HIV burden. Test-and-treat protocols are feasible within high-volume HIV clinics which serve rural and underserved communities to minimize the time to the first appointment to decrease time to viral load suppression.
Resource (Conference Presentation) updated 09/14/2023
This session will help recipient and subrecipient sites to successfully connect their CAREWare and other electronic health information systems with external sources of data to report and monitor HIV care and treatment outcomes. This session will provide practical examples of successful data integration and highlight ongoing issues and costs in long-term management and maintenance.
Resource (Conference Presentation) updated 09/14/2023
The presentation will describe how CAREWare and eligibility integration eased access to services by clients in our jurisdictions. Presenters will be to provide Ryan White jurisdictions with actionable ideas and processes to integrate their CAREWare and eligibility processes to improve access to services, reporting, monitoring, and quality management.
Resource (Conference Presentation) updated 09/14/2023
CAREWare users can provide input on all CAREWare 6 software components, including ease of use, design, reports, and other features. This session will address challenges with specific features like setup, administration, generating reports, and basic data entry.
Resource (Conference Presentation) updated 09/14/2023
This session will focus on key findings and behavioral considerations for long-acting antiretroviral treatment (ART) HIV regimens, given the progress in research, development, and potential approval of these drugs. There will be a brief overview of the ATLAS and FLAIR studies, discussion of the medications, and an outline of the potential impact of the regimens on care delivery models, providers, patients, and payers if they are approved.
Resource (Conference Presentation) updated 09/14/2023